FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186014945> ?p ?o ?g. }

• W3186014945 endingPage "469" @default.
• W3186014945 startingPage "461" @default.
• W3186014945 abstract "Sirolimus is a mammalian target of rapamycin inhibitor (mTORI) with anti-proliferative, antiangiogenic and immunosuppressive properties. While approved in Australia as an anti-rejection medication for renal transplant patients, there is mounting evidence regarding the utility of oral and topical sirolimus in treating a plethora of dermatological conditions or conditions with cutaneous manifestations. Our aim was to present an overview of the evidence for current usage and breadth of the application of sirolimus in dermatology. We carried out a systematic review of all the literature published up to 31 August 2019 on oral and topical sirolimus with respect to dermatological conditions or conditions otherwise relevant to dermatology. While 3368 papers were initially produced in our search, 238 papers met our inclusion criteria and were examined in our review. The conditions examined were categorised into genodermatoses (9 conditions), infection (1 condition), inflammatory/autoimmune (10 conditions), neoplasm (3 conditions) and vascular (17 conditions). We extracted data on first author, publication year, journal, characteristics of the study and study patients, condition, drug modalities, drug efficacy, side effects, blood level of mTORI, co-interventions and follow-up. While there is level 1 evidence for the efficacy of sirolimus in conditions such as tuberous sclerosis complex (TSC) and GVHD prophylaxis, for many other conditions, the evidence is limited to level 4 evidence. Regarding oral systemic therapy, dosing regimens varied with the most common for children 0.8mg/m2 twice daily and for adults 1 mg twice daily. Doses were often adjusted to reach a typical trough level of between 5 and 15 ng/mL, though targets often varied. In the overall majority of cases, side effects were minimal or tolerable, including mucositis, cytopenias, lipid abnormalities and nausea/vomiting, and only a few cases had to stop due to adverse effects. Regarding topical therapy, concentration of formulations varied from 0.1% to 1% and were compounded into creams, ointments or gels and administered typically once or twice per day. The most common side effect was skin irritation. There were a number of limitations to our study. In particular, many of the published studies were case reports or case series with no comparator arm, leading to susceptibility of bias in conclusions drawn, in particular a high likelihood of publication bias. Given the heterogeneity amongst studies, comparisons or aggregation of results was difficult. There continues to be growing use of oral and topical sirolimus in dermatological conditions. It provides new therapeutic options to patients where previous therapies have either failed or are limited due to toxicity. However, further studies are warranted." @default.
• W3186014945 created "2021-08-02" @default.
• W3186014945 creator A5028545621 @default.
• W3186014945 creator A5032562977 @default.
• W3186014945 creator A5058753902 @default.
• W3186014945 date "2021-07-30" @default.
• W3186014945 modified "2023-09-27" @default.
• W3186014945 title "Systematic review of sirolimus in dermatological conditions" @default.
• W3186014945 cites W1502172390 @default.
• W3186014945 cites W1595617857 @default.
• W3186014945 cites W1744607539 @default.
• W3186014945 cites W1941339789 @default.
• W3186014945 cites W1968268983 @default.
• W3186014945 cites W1973616776 @default.
• W3186014945 cites W1975163688 @default.
• W3186014945 cites W1981400002 @default.
• W3186014945 cites W1990066287 @default.
• W3186014945 cites W2026580989 @default.
• W3186014945 cites W2029813711 @default.
• W3186014945 cites W2042285425 @default.
• W3186014945 cites W2049852556 @default.
• W3186014945 cites W2058562532 @default.
• W3186014945 cites W2061115469 @default.
• W3186014945 cites W2069738196 @default.
• W3186014945 cites W2076827030 @default.
• W3186014945 cites W2085928717 @default.
• W3186014945 cites W2123670108 @default.
• W3186014945 cites W2136089017 @default.
• W3186014945 cites W2147425918 @default.
• W3186014945 cites W2155534327 @default.
• W3186014945 cites W2160901124 @default.
• W3186014945 cites W2290639329 @default.
• W3186014945 cites W2472661466 @default.
• W3186014945 cites W2515754624 @default.
• W3186014945 cites W2551971072 @default.
• W3186014945 cites W2605881496 @default.
• W3186014945 cites W2616521638 @default.
• W3186014945 cites W2791734424 @default.
• W3186014945 cites W2805778247 @default.
• W3186014945 cites W2809440034 @default.
• W3186014945 cites W2811414525 @default.
• W3186014945 cites W2884981491 @default.
• W3186014945 cites W2892878289 @default.
• W3186014945 cites W2905280742 @default.
• W3186014945 cites W2908509200 @default.
• W3186014945 cites W2909707191 @default.
• W3186014945 cites W2913026481 @default.
• W3186014945 cites W2914050470 @default.
• W3186014945 cites W2922247092 @default.
• W3186014945 cites W2936144555 @default.
• W3186014945 cites W2938714854 @default.
• W3186014945 cites W2946315754 @default.
• W3186014945 cites W2958551390 @default.
• W3186014945 doi "https://doi.org/10.1111/ajd.13671" @default.
• W3186014945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34328215" @default.
• W3186014945 hasPublicationYear "2021" @default.
• W3186014945 type Work @default.
• W3186014945 sameAs 3186014945 @default.
• W3186014945 citedByCount "5" @default.
• W3186014945 countsByYear W31860149452021 @default.
• W3186014945 countsByYear W31860149452022 @default.
• W3186014945 countsByYear W31860149452023 @default.
• W3186014945 crossrefType "journal-article" @default.
• W3186014945 hasAuthorship W3186014945A5028545621 @default.
• W3186014945 hasAuthorship W3186014945A5032562977 @default.
• W3186014945 hasAuthorship W3186014945A5058753902 @default.
• W3186014945 hasConcept C126322002 @default.
• W3186014945 hasConcept C142724271 @default.
• W3186014945 hasConcept C16005928 @default.
• W3186014945 hasConcept C2777288759 @default.
• W3186014945 hasConcept C2777921159 @default.
• W3186014945 hasConcept C2778980267 @default.
• W3186014945 hasConcept C2779112978 @default.
• W3186014945 hasConcept C2780035454 @default.
• W3186014945 hasConcept C2909963953 @default.
• W3186014945 hasConcept C71924100 @default.
• W3186014945 hasConcept C98274493 @default.
• W3186014945 hasConceptScore W3186014945C126322002 @default.
• W3186014945 hasConceptScore W3186014945C142724271 @default.
• W3186014945 hasConceptScore W3186014945C16005928 @default.
• W3186014945 hasConceptScore W3186014945C2777288759 @default.
• W3186014945 hasConceptScore W3186014945C2777921159 @default.
• W3186014945 hasConceptScore W3186014945C2778980267 @default.
• W3186014945 hasConceptScore W3186014945C2779112978 @default.
• W3186014945 hasConceptScore W3186014945C2780035454 @default.
• W3186014945 hasConceptScore W3186014945C2909963953 @default.
• W3186014945 hasConceptScore W3186014945C71924100 @default.
• W3186014945 hasConceptScore W3186014945C98274493 @default.
• W3186014945 hasIssue "4" @default.
• W3186014945 hasLocation W31860149451 @default.
• W3186014945 hasLocation W31860149452 @default.
• W3186014945 hasOpenAccess W3186014945 @default.
• W3186014945 hasPrimaryLocation W31860149451 @default.
• W3186014945 hasRelatedWork W2148204008 @default.
• W3186014945 hasRelatedWork W2160110272 @default.
• W3186014945 hasRelatedWork W2258473985 @default.
• W3186014945 hasRelatedWork W2676024005 @default.
• W3186014945 hasRelatedWork W2771198366 @default.

• next